Home - Translational Lung Cancer Research

New Impact Factor for Translational Lung Cancer Research: 4

We are pleased to announce that the Translational Lung Cancer Research (TLCR) has attained its latest impact factor update for the 2022 citation year: 4.

Translational Lung Cancer Research 2022 CiteScore Released: 5.9

We are pleased to announce that the Translational Lung Cancer Research (TLCR) has received its 2022 CiteScore: 5.9, ranking 130 out of 366 journals in the Oncology category.

Furthermore, we are delighted to highlight the remarkable achievements made by all AME journals in the CiteScore ranking.

ALK-Positive NSCLC (Ongoing)

This special series on “ALK-Positive NSCLC” is edited by Dr. Justin F. Gainor and Dr. Jessica J. Lin from the Department of Medicine, Harvard Medical School, Boston, USA. This special series aims to provide an updated overview of the most recent acquisitions and future perspectives.

Interviews with Outstanding Authors (2022)

In 2022, many authors make outstanding contributions to our journal. Their articles published with us have received very well feedback in the field and stimulate a lot of discussions and new insights among the peers.

Hereby, we would like to highlight some of our outstanding authors, with a brief interview of their thoughts and insights as authors. Allow us to express our heartfelt gratitude for their tremendous effort and valuable contributions to the scientific process.

TLCR Annual Report 2022

Welcome to the 2022 annual report for Translational Lung Cancer Research. In 2022, the TLCR has continued its mission to increase the quality and impact of the journal, and to provide readers with a novel, well-organized, informative, enlightening and educational journal.

We would like to sincerely thank our Editorial Board Members, Guest editors, Reviewers, Authors, Readers for all your supports and contributions to TLCR in 2022, and we look forward to continuing our work with you in the new year.

Reviewer of the Month (2023)

In 2023, TLCR reviewers continue to make outstanding contributions to the peer review process. They demonstrated professional effort and enthusiasm in their reviews and provided comments that genuinely help the authors to enhance their work.

Hereby, we would like to highlight some of our outstanding reviewers, with a brief interview of their thoughts and insights as a reviewer. Allow us to express our heartfelt gratitude for their tremendous effort and valuable contributions to the scientific process.

‹ ›

Vol 12, No 9 (September, 2023)

About tlcr

Manuscript Submission

AME Editing Service

Reprint & Permission

Advertising

Contact us

General editorial enquiries:
Email: editor@tlcr.org
Copyright related contact:
Email: permissions@amegroups.com
Commercial Sales contact (Reprints, advertising, etc.):
Email: sales@amegroups.com

TLCR Chinese Edition more

免疫治疗是晚期非小细胞肺癌去化疗的关键，或还是未到时候？

免疫检查点抑制剂（immune checkpoint... More >>

晚期或转移性非小细胞肺癌一线免疫治疗中，肿瘤细胞PD-L1表达的阈值究竟在哪

对于晚期或转移性非小细胞肺癌（non-small cell lung... More >>

KEYNOTE-042研究：降低帕博利珠单抗单药一线治疗的PD-L1阈值是个好主意吗？

在针对程序性死亡1（programmed death 1，PD-1）或程序性死亡配体1（programmed... More >>

Editorial

Are current lung cancer screening guidelines and programs racially biased?

Asha Bonney, Daniel Steinfort, Renee Manser

PDF Pages: 1834-1837 Full Text (20) COI Form Open Access

The role of laboratory tests as a prognostic marker for immune-checkpoint therapy in non-small cell lung cancer

Prashanth Ashok Kumar, Alina Basnet

PDF Pages: 1838-1841 Full Text (26) COI Form Open Access

Differences and similarities of GTF2I mutated thymomas in different Eurasian ethnic groups

Matthias Lang, Daniel Kazdal, Isabelle Mohr, Chrysanthi Anamaterou

PDF Pages: 1842-1844 Full Text (24) COI Form Open Access

Are radiomic signatures ready for incorporation in the clinical pipeline?

Apurva Singh, Leonid Roshkovan, Jeffrey C. Thompson, Despina Kontos, Sharyn I. Katz

PDF Pages: 1845-1849 Full Text (21) COI Form Open Access

Original Article

Thyroid transcription factor-1 (TTF-1) expression and the efficacy of combination therapy with immune checkpoint inhibitors and cytotoxic chemotherapy in non-squamous non-small cell lung cancer

Hirokazu Iso, Kakeru Hisakane, Erika Mikami, Takahiro Suzuki, Satoru Matsuki, Kenichiro Atsumi, Kohji Nagata, Masahiro Seike, Takashi Hirose

PDF Pages: 1850-1861 Full Text (44) Reporting Checklist Data Sharing Statement Peer Review File COI Form Open Access

Characteristics and prognostic analysis of patients with detected KRAS mutations in resected lung adenocarcinomas by peptide nucleic acid-locked nucleic acid polymerase chain reaction (PNA-LNA PCR) clamp method

Tatsuya Hashimoto, Yoshihisa Owada, Hiroshi Katagiri, Kazuhiro Yakuwa, Katuya Tyo, Mayu Sugai, Itaru Fuzimura, Yu Utsumi, Masachika Akiyama, Hiromi Nagashima, Hiroshi Terasaki, Naoki Yanagawa, Hajime Saito, Tamotsu Sugai, Makoto Maemondo

PDF Pages: 1862-1875 Full Text (28) Reporting Checklist Data Sharing Statement Peer Review File COI Form Open Access

HSP90 expression is associated with outcome in pulmonary carcinoid tumor patients

Jenni Niinimäki, Harri Sihto, Johanna Arola, Tiina Vesterinen

PDF Pages: 1876-1886 Full Text (24) Reporting Checklist Data Sharing Statement Peer Review File COI Form Open Access

Risk factors for symptomatic malignant pleural effusion recurrence in patients with actionable mutations in advanced lung adenocarcinoma

Ke Xu, Xiaodi Wu, Lu Chen, Jingyuan Xie, Xin Hua, Mo Chen, Yuxin Jiang, Hongbing Liu, Fang Zhang, Tangfeng Lv, Yong Song, Ping Zhan

PDF Pages: 1887-1895 Full Text (23) Reporting Checklist Data Sharing Statement Peer Review File COI Form Open Access

The differential prognostic implications of PD-L1 expression in the outcomes of Filipinos with EGFR-mutant NSCLC treated with tyrosine kinase inhibitors

Herdee Gloriane C. Luna, Marcelo Severino Imasa, Necy Juat, Katherine V. Hernandez, Treah May Sayo, Gloria Cristal-Luna, Sheena Marie Asur-Galang, Mirasol Bellengan, Kent John Duga, Bien Brian Buenaobra, Marvin I. De los Santos, Daniel Medina, Jamirah Samo, Venus Minerva Literal, Neil Andrew Bascos, Sullian Sy-Naval

PDF Pages: 1896-1911 Full Text (21) Reporting Checklist Data Sharing Statement Peer Review File COI Form Open Access

Real-world clinical evidence of lazertinib use in acquired EGFR T790M mutated non-small cell lung cancer

Sehhoon Park, Hyun Ae Jung, Se-Hoon Lee, Jin Seok Ahn, Myung-Ju Ahn, Jong-Mu Sun

PDF Pages: 1912-1922 Full Text (21) Reporting Checklist Data Sharing Statement Peer Review File COI Form Open Access

Combined indocyanine green and medical glue enables stable and precise position in animal studies: promising for fluorescence-guided pulmonary ground glass nodule resection

Ziyang Wang, Yunlong Li, Jianghong Yu, Huiming Cai, Yiqing Wang

PDF Pages: 1923-1934 Full Text (25) Reporting Checklist Data Sharing Statement Peer Review File COI Form Open Access

Superior clinical outcomes in patients with non-small cell lung cancer harboring multiple ALK fusions treated with tyrosine kinase inhibitors

Qi Wei, Yuanyuan Zhang, Yongsheng Wang, Aakash Desai, Sihan Tan, Qin Huang, Xin Pu, Panwen Tian, Yalun Li

PDF Pages: 1935-1948 Full Text (23) Reporting Checklist Data Sharing Statement Peer Review File COI Form Open Access

First-line versus second-line use of pralsetinib in treatment of rearranged during transfection (RET) fusion-positive advanced non-small cell lung cancer: a cost-effectiveness analysis

Wenjie Liu, Gengwei Huo, Mengjie Li, Peng Chen

PDF Pages: 1949-1958 Full Text (20) Reporting Checklist Peer Review File COI Form Open Access

Editorial Commentary

Characterization of the tumor microenvironment by single-cell RNA sequencing in non-small cell lung cancer treated with neo-adjuvant immunotherapy

Laurenz Nagl, Lena Horvath, Stefan Salcher, Dominik Wolf, Andreas Pircher

PDF Pages: 1959-1965 Full Text (22) COI Form Open Access

Review Article

Targeted therapy for non-small cell lung cancer: current standards and the promise of the future

Bryan A. Chan, Brett G.M. Hughes

Beyond ALK-RET, ROS1 and other oncogene fusions in lung cancer

Takashi Kohno, Takashi Nakaoku, Koji Tsuta, Katsuya Tsuchihara, Shingo Matsumoto, Kiyotaka Yoh, Koichi Goto

Global trends of lung cancer mortality and smoking prevalence

Farhad Islami, Lindsey A. Torre, Ahmedin Jemal

Known and putative mechanisms of resistance to EGFR targeted therapies in NSCLC patients with EGFR mutations—a review

Erin L. Stewart, Samuel Zhixing Tan, Geoffrey Liu, Ming-Sound Tsao

Tackling ALK in non-small cell lung cancer: the role of novel inhibitors

Francesco Facchinetti, Marcello Tiseo, Massimo Di Maio, Paolo Graziano, Emilio Bria, Giulio Rossi, Silvia Novello

Circulating tumor cells versus circulating tumor DNA in lung cancer—which one will win?

Silvia Calabuig-Fariñas, Eloísa Jantus-Lewintre, Alejandro Herreros-Pomares, Carlos Camps

Editorial

Whacking a mole-cule: clinical activity and mechanisms of resistance to third generation EGFR inhibitors in EGFR mutated lung cancers with EGFR-T790M

Daniel B. Costa, Susumu S. Kobayashi

Review Articles

Management of ground-glass opacities: should all pulmonary lesions with ground-glass opacity be surgically resected?

Yoshihisa Kobayashi, Tetsuya Mitsudomi

KRAS mutant NSCLC, a new opportunity for the synthetic lethality therapeutic approach

Javier de Castro Carpeño, Cristóbal Belda-Iniesta

Review Article on Lung Cancer Diagnostics and Treatments 2015: A Renaissance of Patient Care

Immune checkpoint inhibitors in clinical practice: update on management of immune-related toxicities

Jeryl Villadolid, Asim Amin

Review Article

Targeted therapy for non-small cell lung cancer: current standards and the promise of the future

Bryan A. Chan, Brett G.M. Hughes

Known and putative mechanisms of resistance to EGFR targeted therapies in NSCLC patients with EGFR mutations—a review

Erin L. Stewart, Samuel Zhixing Tan, Geoffrey Liu, Ming-Sound Tsao

Global trends of lung cancer mortality and smoking prevalence

Farhad Islami, Lindsey A. Torre, Ahmedin Jemal

Recurrence after surgery in patients with NSCLC

Hidetaka Uramoto, Fumihiro Tanaka

Beyond ALK-RET, ROS1 and other oncogene fusions in lung cancer

Takashi Kohno, Takashi Nakaoku, Koji Tsuta, Katsuya Tsuchihara, Shingo Matsumoto, Kiyotaka Yoh, Koichi Goto

Non-small cell lung cancer: current treatment and future advances

Cecilia Zappa, Shaker A. Mousa

Phosphatidylinositol 3-kinase-AKT-mammalian target of rapamycin (PI3K-Akt-mTOR) signaling pathway in non-small cell lung cancer

Po Yee Yip

Lung cancer molecular epidemiology in China: recent trends

Caicun Zhou

The role of the immune system in non-small cell lung carcinoma and potential for therapeutic intervention

Joanna Domagala-Kulawik

Concordance of IHC, FISH and RT-PCR for EML4-ALK rearrangements

Cristina Teixidó, Niki Karachaliou, Vicente Peg, Ana Gimenez-Capitan, Rafael Rosell

ALK and crizotinib: after the honeymoon…what else? Resistance mechanisms and new therapies to overcome it

Christian Rolfo, Francesco Passiglia, Marta Castiglia, Luis E. Raez, Paul Germonpre, Ignacio Gil-Bazo, Karen Zwaenepoel, Annemieke De Wilde, Giuseppe Bronte, Antonio Russo, Jan P. Van Meerbeeck, Paul Van Schil, Patrick Pauwels

Highlighted Reports in European Lung Cancer Conference

Preoperative mediastinal lymph node staging for non-small cell lung cancer: 2014 update of the 2007 ESTS guidelines

Paul De Leyn, Christophe Dooms, Jaroslaw Kuzdzal, Didier Lardinois, Bernward Passlick, Ramon Rami-Porta, Akif Turna, Paul Van Schil, Frederico Venuta, David Waller, Walter Weder, Marcin Zielinski

Review Article on Lung Cancer Diagnostics and Treatments 2015: A Renaissance of Patient Care

Immune checkpoint inhibitors in clinical practice: update on management of immune-related toxicities

Jeryl Villadolid, Asim Amin

Circulating DNA in diagnosis and monitoring EGFR gene mutations in advanced non-small cell lung cancer

Paola Bordi, Marzia Del Re, Romano Danesi, Marcello Tiseo

Novel radiotherapy approaches for lung cancer: combining radiation therapy with targeted and immunotherapies

Charles B. Simone II, Stuart H. Burri, John H. Heinzerling

Angiogenesis inhibition as a therapeutic strategy in non-small cell lung cancer (NSCLC)

Richard D. Hall, Tri M. Le, Daniel E. Haggstrom, Ryan D. Gentzler

Original Article

Prognostic value of Twist in lung cancer: systematic review and meta-analysis

Junli Zeng, Ping Zhan, Guannan Wu, Wen Yang, Wenjun Liang, Tangfeng Lv, Yong Song

BRAF mutations in non-small cell lung cancer

Peter P. Luk, Bing Yu, Chiu Chin Ng, Belinda Mercorella, Christina Selinger, Trina Lum, Steven Kao, Sandra A. O’Toole, Wendy A. Cooper

The suitability of small biopsy and cytology specimens for EGFR and other mutation testing in non-small cell lung cancer

Shu Wang, Bing Yu, Chiu Chin Ng, Belinda Mercorella, Christina I. Selinger, Sandra A. O’Toole, Wendy A. Cooper

Itraconazole can inhibit malignant pleural effusion by suppressing lymphangiogenesis in mice

Yunfen Wang, Yanwen Yao, Hongbin Liu, Xingqun Ma, Tangfeng Lv, Dongmei Yuan, Xinwu Xiao, Jie Yin, Yong Song

Ratio of maximum standardized uptake value to primary tumor size is a prognostic factor in patients with advanced non-small cell lung cancer

Fangfang Chen, Yanwen Yao, Chunyan Ma, Xingqun Ma, Zhaofeng Wang, Tangfeng Lv, Xinwu Xiao, Jie Yin, Yong Song

Advanced proton beam dosimetry part II: Monte Carlo vs. pencil beam-based planning for lung cancer

Dominic Maes, Jatinder Saini, Jing Zeng, Ramesh Rengan, Tony Wong, Stephen R. Bowen

The cytokinesis-blocked micronucleus assay as a novel biomarker for selection of lung cancer screening participants

Randa A. El-Zein, Carol J. Etzel, Reginald F. Munden

The use of TCP based EUD to rank and compare lung radiotherapy plans: in-silico study to evaluate the correlation between TCP with physical quality indices

Abdulhamid Chaikh, Jacques Balosso

Review Article

Beyond ALK-RET, ROS1 and other oncogene fusions in lung cancer

Takashi Kohno, Takashi Nakaoku, Koji Tsuta, Katsuya Tsuchihara, Shingo Matsumoto, Kiyotaka Yoh, Koichi Goto

Overview of clinicopathologic features of ALK-rearranged lung adenocarcinoma and current diagnostic testing for ALK rearrangement

Hyojin Kim, Jin-Haeng Chung

Neoadjuvant and adjuvant epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) therapy for lung cancer

Haoran Zhai, Wenzhao Zhong, Xuening Yang, Yi-Long Wu

Known and putative mechanisms of resistance to EGFR targeted therapies in NSCLC patients with EGFR mutations—a review

Erin L. Stewart, Samuel Zhixing Tan, Geoffrey Liu, Ming-Sound Tsao

Clinical trials for lung cancer in China

Fei-Yu Niu, Wen-Zhao Zhong, Qing Zhou, Yi-Long Wu

Recurrence after surgery in patients with NSCLC

Hidetaka Uramoto, Fumihiro Tanaka

Prognostic markers in lung cancer: is it ready for prime time?

Chang-Qi Zhu, Ming-Sound Tsao

Potential biomarkers for lung cancer screening

Gabriella Sozzi, Mattia Boeri

Particle therapy in non-small cell lung cancer

Zhongxing Liao, Charles B. Simone II

Computer Aided Nodule Analysis and Risk Yield (CANARY) characterization of adenocarcinoma: radiologic biopsy, risk stratification and future directions

Ryan Clay, Srinivasan Rajagopalan, Ronald Karwoski, Fabien Maldonado, Tobias Peikert, Brian Bartholmai

Immunotherapy and radiation therapy for operable early stage and locally advanced non-small cell lung cancer

Neil K. Taunk, Andreas Rimner, Melissa Culligan, Joseph S. Friedberg, Julie Brahmer, Jamie Chaft

Combining immunotherapy and radiation therapy for small cell lung cancer and thymic tumors

Suchit H. Patel, Andreas Rimner, Roger B. Cohen

Intraoperative near-infrared imaging of mesothelioma

Gregory Thomas Kennedy, Andrew Newton, Jarrod Predina, Sunil Singhal

BAP1, a tumor suppressor gene driving malignant mesothelioma

Mitchell Cheung, Joseph R. Testa

Uncovering the immune tumor microenvironment in non-small cell lung cancer to understand response rates to checkpoint blockade and radiation

Jonathan E. Schoenhals, Steven N. Seyedin, Clark Anderson, Eric D. Brooks, Yun R. Li, Ahmed I. Younes, Sharareh Niknam, Ailin Li, Hampartsoum B. Barsoumian, Maria Angelica Cortez, James W. Welsh

Diagnostic and prognostic biomarkers for malignant mesothelioma: an update

Zhongjian Chen, Giovanni Gaudino, Harvey I. Pass, Michele Carbone, Haining Yang

Immunotherapy for malignant pleural mesothelioma: current status and future directions

Jordan Dozier, Hua Zheng, Prasad S. Adusumilli

Biology and clinical significance of circulating tumor cell subpopulations in lung cancer

Linda O’Flaherty, Harriet Wikman, Klaus Pantel

Routine clinical use of circulating tumor cells for diagnosis of mutations and chromosomal rearrangements in non-small cell lung cancer—ready for prime-time?

Emma Pailler, Vincent Faugeroux, Marianne Oulhen, Cyril Catelain, Françoise Farace

Challenges and unanswered questions for the next decade of circulating tumour cell research in lung cancer

Sumitra Mohan, Francesca Chemi, Ged Brady

Biophysical technologies for understanding circulating tumor cell biology and metastasis

Derrick W. Su, Jorge Nieva

Clinical utility of circulating tumor cells in patients with non-small-cell lung cancer

Marianna Gallo, Antonella De Luca, Monica Rosaria Maiello, Amelia D’Alessio, Claudia Esposito, Nicoletta Chicchinelli, Laura Forgione, Maria Carmela Piccirillo, Gaetano Rocco, Alessandro Morabito, Gerardo Botti, Nicola Normanno

Integrating immunotherapy into chemoradiation regimens for medically inoperable locally advanced non-small cell lung cancer

Salma K. Jabbour, Abigail T. Berman, Charles B. Simone II

Editorial

An alternative way to initiate Notch1 signaling in non-small cell lung cancer

Yi-Lin Yang, David Jablons, Liang You

Combination MET- and EGFR-directed therapy in MET-overexpressing non-small cell lung cancers: time to move on to better biomarkers?

Fernando C. Santini, Siddharth Kunte, Alexander Drilon

Systematic Review and Meta-analysis

Association of the metformin with the risk of lung cancer: a meta-analysis

Li Wang, Yong Song, Guan-Nan Wu, Dong-Mei Yuan

China Lung Cancer Research Highlight

Dll4/Notch1 signaling from tip/stalk endothelial cell specification to stroma-dependent lung tumor inhibition: a flavor of Dll4/Notch1 pleiotropy in tumor cell biology

Maria Felice Brizzi, Paola Defilippi

Editorials

Dulanermin in cancer therapy: Still much to do

Cristina Quintavalle, Gerolama Condorelli

Review Articles

EGFR molecular testing in African-American non-small cell lung cancer patients - a review of discrepant data

Bradley T. Clifford, Pingfu Fu, Nathan A. Pennell, Balazs Halmos, Rom S. Leidner

Copy number gains of FGFR1 and 3q chromosome in squamous cell carcinoma of the lung

Pedro Mendez, Jose Luis Ramirez

Role of HGF/MET axis in resistance of lung cancer to contemporary management

Kanwal Pratap Singh Raghav, Ana Maria Gonzalez-Angulo, George R. Blumenschein Jr

Circulating soluble intercellular adhesion Molecule-1 in lung cancer: a systematic review

Xiaoling Gu, Chunyan Ma, Dongmei Yuan, Yong Song

Ceritinib

Clinical development and approval of second generation ALK inhibitors for ALK rearranged lung cancer

Daniel B. Costa

Onartuzumab plus erlotinib

Targeting MET in NSCLC: looking for a needle in a haystack

Lorenza Landi, Federico Cappuzzo

Nivolumab

Nivolumab (anti-PD-1, BMS-936558, ONO-4538) in patients with advanced non-small cell lung cancer

Arun Rajan, James L. Gulley

Brief Report

The role of Imaging and Radiation Oncology Core for precision medicine era of clinical trial

Ying Xiao, Mark Rosen

Review Article on Update on Pathology and Predictive Biomarkers of Lung Cancer

Biology of invasive mucinous adenocarcinoma of the lung

Yoon Jin Cha, Hyo Sup Shim

Immunohistochemistry for predictive biomarkers in non-small cell lung cancer

Mari Mino- Kenudson

Below are the latest Translational Lung Cancer Research articles published online ahead of print publication.

Original Article

Impact of RBM10 and PD-L1 expression on the prognosis of pathologic N1–N2 epidermal growth factor receptor mutant lung adenocarcinoma

Tetsuya Isaka, Yohei Miyagi, Tomoyuki Yokose, Haruhiro Saito, Rika Kasajima, Kozue Watabe, Naoko Shigeta, Noritake Kikunishi, Shunsuke Shigefuku, Kotaro Murakami, Hiroyuki Adachi, Takuya Nagashima, Hiroyuki Ito

Published online: 25 September 2023

Journal Highlight more

Translational Lung Cancer Research is an international, peer-reviewed, open-access journal indexed by Science Citation Index Expanded (SCIE) and PubMed/PubMed Central, focusing on cutting-edge development on the transition from preclinical to clinical research, including but not limited to multimodality therapy, markers, imaging, tumor biology, pathology, chemoprevention, and technical advances related to lung cancer and relevant thoracic diseases.